Overall	Events, n	Median, months (95% CI)
Overall (n = 152)	99	8.5 (6.9, 11.0)

Patients at risk

152 118 86 56 37 26 16 11 8 6 4 1 1 1 0 0

Age	Events, n	Median, months (95% CI)
<75 years (n = 84)	55	8.3 (6.8, 11.0)
≥75 years (n = 68)	44	9.7 (6.3, 14.5)
<80 years (n = 115)	77	8.5 (6.9, 11.0)
≥80 years (n = 37)	22	8.6 (5.5, 27.6)

Patients at risk

<75 years	84	69	48	29	18	11	11	8	6	5	4	1	1	1	0
≥75 years	68	49	38	27	19	15	5	3	2	1	0	0	0	0	0
<80 years	115	92	66	43	28	18	12	9	7	5	4	1	1	1	0
≥80 years	37	26	20	13	9	8	4	2	1	1	0	0	0	0	0

Line of therapy	Events, n	Median, months (95% CI)
Treatment-naïve (n = 69)	41	8.6 (6.8, 12.2)
Previously treated (n = 83)	58	8.3 (5.8, 11.0)

Patients at risk:

Treatment-naïve	69	53	39	24	16	13	11	7	5	4	2	0	0	0	0
Previously treated	83	65	47	32	21	13	5	4	3	2	2	1	1	1	0

Prior platinum-based chemotherapy for metastatic disease	Events, n	Median, months (95% CI)
Yes (n = 74)	50	9.5 (5.8, 13.8)

Patients at risk:

Yes	74	58	42	30	21	13	5	4	3	2	2	1	1	1	0

Figure S4. Progression-free survival by investigator assessment. CI, confidence interval.